


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
JNJ
Johnson & Johnson
$227.29
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Investors confidence is positive
Technical Indicators

5+ Days Up
JNJ Price Performance
$206.95 (+9.83%)
$186.26 (+22.03%)
$178.43 (+27.38%)
$157.25 (+44.54%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive

Pays a reliable dividend

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market

Trading below its fair value
![]()
JNJ Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook
JNJ has Low risk level

Average key support and resistance price levels
NBTX
21.89
-2.36%
BLTE
169.02
+2.04%
ANNX
6.52
+3.66%
SNDX
20.59
+0.19%
REGN
749.44
-0.22%
What is JNJ current stock price?
What are JNJ stock strengths?
What is JNJ Risk Level?
What is JNJ market cap and volume?
What is JNJ current Stock IQ?
Should I buy JNJ stock right now?
Is JNJ a Strong Buy right now?
What does a 'Strong Buy' rating mean for JNJ?
What does a 'Strong Sell' rating mean for JNJ?
What factors influence JNJ's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
JNJ
Johnson & Johnson
Current Price
$227.29
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Investors confidence is positive
Technical Indicators

5+ Days Up
Linked to JNJ
NBTX
21.89
-2.36%
BLTE
169.02
+2.04%
ANNX
6.52
+3.66%
SNDX
20.59
+0.19%
REGN
749.44
-0.22%

JNJ Price Performance
$206.95 (+9.83%)
$186.26 (+22.03%)
$178.43 (+27.38%)
$157.25 (+44.54%)
JNJ Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive

Pays a reliable dividend

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market

Trading below its fair value
![]()
JNJ Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook
JNJ has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Jan 28, 2026
Upgrade
Overweight
Morgan Stanley
Dec 17, 2025
Price Target Raised
Neutral
BofA
Dec 12, 2025
Reiterate
Outperform
RBC
Dec 12, 2025
Reiterate
Buy
Citigroup
Dec 11, 2025
Reiterate
Buy
Guggenheim
JNJ Stock IQ
JNJ Latest Analysis
Scotiabank Raises Johnson & Johnson (JNJ) Target on Strong Quarterly Results. Johnson &. Johnson (NYSE:JNJ) is included among the 12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds. On January 22 Scotiabank lifted its price target on Johnson &. Johnson (NYSE:JNJ) to $265 from $230. The firm reiterated an Outperform rating after the companys Q4 results. The bigger takeaway was how well J&.J [….]
Today
Top Stock Reports for Johnson & Johnson Netflix & Arista Networks. JNJs Q4 beat Netflixs subscriber surge and Arista Networks cloud demand highlight why these stocks headline todays top research reports.
Wed Jan 28, 2026
Morgan Stanley Upgrades Johnson & Johnson (JNJ). Fintel reports that on January 28 2026 Morgan Stanley upgraded their outlook for Johnson &. Johnson (NYSE:JNJ) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 4.08% Downside
Wed Jan 28, 2026
Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?. JNJ beat Q4 expectations and guided 2026 sales to be in the range of $100-$101B with Innovative Medicine and MedTech growth offsetting Stelara LOE.
Wed Jan 28, 2026
Johnson & Johnson: Strong Momentum Heading Into 2026.
Wed Jan 28, 2026
Johnson & Johnson upgraded at Morgan Stanley on growth outlook.
Wed Jan 28, 2026
Morgan Stanley upgrades J&J on new drug launches.
Wed Jan 28, 2026
Morgan Stanley upgrades Johnson & Johnson sees upside on robust drug pipeline. Morgan Stanleys price target implies that shares of Johnson & Johnson could rise another 17%.
Wed Jan 28, 2026
J&J Secures FDA Approval For DARZALEX FASPRO Combo In Newly Diagnosed Multiple Myeloma . (RTTNews) - Drug major Johnson & Johnson (JNJ) announced Tuesday that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) -based quadruplet regimen has received the United States Food and Drug Administration approval to treat adult patients with newly diagnosed multiple myeloma or NDMM
Wed Jan 28, 2026
Johnson & Johnson stock rating upgraded by Morgan Stanley on growth outlook.
Wed Jan 28, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.